Skip to content

Virtual Reality Trial Using EaseVRx For Chronic Low Back Pain

Safety and Effectiveness of Virtual Reality Utilizing EaseVRx for the Reduction of Chronic Pain and Opioid Use

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04415177
Enrollment
188
Registered
2020-06-04
Start date
2020-07-01
Completion date
2021-04-30
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lower Back Pain

Keywords

Virtual Reality, Chronic Lower Back Pain, Analgesia

Brief summary

Randomized, 2-arm parallel group clinical trial evaluating the effectiveness of a self-administered Virtual Reality program for the treatment of chronic lower back pain compared to a placebo VR program.

Detailed description

A randomized, 2-arm parallel-group clinical trial evaluating the effectiveness of a self-administered Virtual Reality (VR) program for the treatment of chronic lower back pain. The primary objective of this study is to assess the impact of skills-based VR on changes in patient-reported pain and pain interference over the course of an 8-week intervention as well as compared to a placebo VR condition. The secondary objective is to assess the impact of skill-based VR on changes in patient-reported satisfaction over the course of an 8-week intervention and compared to a placebo VR condition. A tertiary objective is to assess the impact of skills-based VR on changes in patient-reported opioid use, physical function, behavioral skills development, and health outcomes immediately following the intervention relative to a pre-intervention baseline and compared to a placebo VR condition. An exploratory objective is to assess the impact of skills-based VR on changes in patient-reported pain levels, opioid use, physical function, behavioral skills development, health outcomes, and satisfaction at the 24-week post-intervention time point and compared to a placebo VR condition.

Interventions

DEVICEEaseVRx headset with active intervention

VR software developed by AppliedVR informed by evidence-based cognitive behavioral therapy principles, biofeedback and mindfulness strategies for pain management.

DEVICEEaseVRx headset without active intervention

VR software developed by AppliedVR with neutral non-interactive content.

Sponsors

AppliedVR Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Men and women 18-85 years old * Diagnosis of low back pain without radicular symptoms * Pain duration of at least 6 months * Average pain intensity of at least 4 on the 0-10 DoD/VA Pain Scale for the past month at screening * English fluency * Willing to comply with study procedures/restrictions

Exclusion criteria

* Unable to understand the goals of the study due to cognitive difficulty * Current or prior diagnosis of epilepsy, seizure disorder, dementia, migraines or other neurological disease that may prevent the use of VR * Medical condition predisposing to nausea or dizziness * Hypersensitivity to flashing light or motion * No stereoscopic vision or severe hearing impairment * Injury to eyes, face or neck that prevents comfortable use of VR * Pain related to cancer * Active suicidal ideation or severe depression * Previous use of EaseVR for pain * Current participation in any interventional research study or completed participation in past 2 months * Currently pregnant or planning to become pregnant * Does not have access to WIFI during participation in study * Currently works at or has an immediate family member who works for a digital health company or pharmaceutical company that provides treatments for acute or chronic pain

Design outcomes

Primary

MeasureTime frameDescription
Department of Defense (DoD)/VA Pain scaleThe primary efficacy endpoint is the change from study baseline to Day 56DoD/VA Pain scale measures pain intensity, and inference around activity, sleep, mood, and stress, each on an 11-point scale. The max score is 50 and the minimum is 0. The higher the score the worse the outcome. This will be assessed twice weekly during the 8-week intervention intervention period.

Secondary

MeasureTime frameDescription
Patient's Global Impression of Change Scaletwice weekly during 8-week intervention, Day 56Single item Patient's Global Impression of Change Scale (PGIC), self-reported the level of change (if any) in activity limitations, symptoms, emotions, and overall quality of life-related to your painful condition on a 7-point scale. The higher the number the better the outcome.

Other

MeasureTime frameDescription
Custom Opioid Use SurveyBaseline, Day 56Custom survey assesses the use of opioids, frequency of use, dose of medication, happiness with regimen, and interest in change in treatment.
Patient-Reported Outcomes Measurement Information System (PROMIS) Physical FunctionBaseline, Day 56This 6-item PROMIS physical function measure assesses physical function such as (chores, running errands) on a 5-point scale. The max score is 30 and the minimum is 6. The higher the score the better the outcome.
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep DisturbanceBaseline, Day 566-item PROMIS sleep disturbance measure assesses the level of sleep disturbance on a 5-point scale. The max score is 30 and the minimum is 6. The higher the score the worse the outcome.
Pain Self-efficacy QuestionnaireBaseline, Day 562-item PSEQ (PSEQ-2) assesses pain self-efficacy on a 7-point scale. The max score is 12 and the minimum is 0. The higher the score the better the outcome.
Device utilization Questionnairetwice weekly during 8-week intervention, Day 56Self-reported number of VR sessions completed since the participant last reported. The scale is 0-4 or more. The higher than number the higher the usage.
Chronic Pain Acceptance QuestionnaireBaseline, Day 568-item Chronic Pain Acceptance (CPAQ-8) questionnaire assesses acceptance or psychological flexibility associated with chronic pain on a 7-point scale. The max score is 56 and the minimum is 8. The higher the score the better the outcome.
Behavioral Skills AssessmentDay 56Custom survey assesses the development of skills to manage pain outside of the VR headset. This is only included in the EaseVRx condition. There are 4 knowledge questions. These are on a 1-5 scale from do not agree to completely agree. The skills questions are on a 0 to 10 scale with 0 being not at all confident and 10 being very confident.
Health Utilization Outcomes QuestionnaireDay 56Questionnaire on the frequency of steroid injections, lower back surgery, emergency department visits, hospital admissions, and unplanned physician visits over various time periods. The first part of each of these questions asks if they have had the service and then the second part asks for the frequency.
VR Use DataDay 1 through Day 56VR use calculated as the total number of sessions launched. It will be continuous data stored on the headset.
Pain Catastrophizing ScaleBaseline, Day 564 items from the Pain Catastrophizing Scale (PCS) assesses frequency of pain-related thoughts and feelings on a 5-point scale. The max score is 16 and the minimum is 0. The higher the score the worse the outcome.
VR Satisfaction ScaleDay 56Satisfaction ratings regarding the ability of the VR program to relieve pain symptoms on a 5-point scale. One is defined as strongly disagree with the statement and five is defined as strongly agree. The higher the number the better the outcome.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026